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SUMMARY.-Selection of cytostatic agents for intrathecal administration is
the subject of this paper.
Both the toxic side effects-destruction of blood-brain barrier and change
of body weight-and the cytostatic effects on intracranially transplanted
Yoshida ascites sarcoma were investigated of intrathecal administration of
various cytostatic agents. As a result, it may be concluded that Metho-
trexate and Endoxan and lower dose of mitomycin C are suitable drugs for
intrathecal chemotherapy.
Based on these findings, clinical cases of malignant brain tumours were
treated with intrathecal chemotherapy.
Grateful acknowledgement is made to Professor Dennosuke Jinnai for his
constant interest and guidance in this investigation.
FOR the chemotherapy of brain tumours, administration techniques of cyto-
static agents are usually divided into three routes: systemic, intra-arterial, and
intrathecal or intratumoral administration.
Intrathecal administration, however, is not so frequently used, for this route of
application may subject the normal brain tissue to the action of the drug and be
liable to cause severe neurological dysfunction (Heppner, Diemath and Jenkner,
1961; Heppner and Diemath, 1963; Hockey and Mealey, 1965; Franco and
Mealey, 1967).
The purpose of the present paper is to select cytostatic agents for intrathecal
chemotherapy.
MATERIALS AND METEODS
Experiments were conducted under the following headings:
I. To select cytostatic agents for intrathecal administration from the viewpoint of
toxic side effects.
(a) Destruction of the blood-brain barrier-brain oedema-which can be
presumed from measuring the uptake ratio by brain tissue of RISA (radio-
iodinated serum albumin) injected intravenously, was studied after intracisternal
administrations of cytostatic agents in rabbits.
(b) Changes ofbody weight were checked following intrathecal administration
of cytostatic agents in rats.
II. To evaluate the effect of intrathecal administration of cytostatic agents on
survival period of intracranially tumour transplanted rats.T. HAYAKAWA ET AL.
I. (a) Four rabbits weighing 1*8 to 2*2 kg. in each group were employed in this
study. Each animal was anaesthetized lightly with sodium pentobarbital,
cisternal puncture was accomplished using a 25-gauge needle and immediately
afterwards 0.5 ml. of cerebrospinal fluid per kg. of body weight was withdrawn
slowly, and various doses of cytostatic agent were injected intracisternally. The
cytostatic agent was dissolved in the same volume of sterile water as that of
cerebrospinal fluid withdrawn and was prepared by the addition of sodium
chloride to isotonic solution. At 24 hours later RISA 10 ,uCi. per kg., which hardly
penetrates the normal blood-brain barrier and produces no alterations in the
vessels of the brain, was given intravenously. At 48 hours after administration
ofthe cytostatic agent, intravenous sodium pentobarbital was used as anaesthetic
agent and left thoracotomy was performed. A sample of blood serum was
collected by cardiac puncture for counting radioactivity and the animal was
exsanguinated by an incision in the right auricle. Through a catheter inserted
into the aorta, the brain and upper body were perfused with 200 ml. of saline.
The entire brain was then removed, rinsed with saline immediately and blotted
with reasonable firmness on a piece of filter paper. After the pia mater had been
removed, approximately 1 g. each of brain tissue was excised from the right
parietal lobe and from the cerebellum, was pushed to the bottom of a test tube,
and weighed accurately. Radioactivities of the brain tissues and sera were
counted in a scintillation counter. Uptake ratio by brain tissue of RISA was
calculated by the following formula:
Counts/min./g. of brain tissue x 104
Counts/min./ml. of serum
I. (b) Five rats weighing approximately 100 g. in each group were employed in
this experiment. The animals were anaesthetized with ether and the cytostatic
agent was injected intrathecally. The technique employed has been described by
Lindberg and Ernster (1950). The cytostatic agent was dissolved in 0.1 ml. of
water per 100 g. of body weight and prepared by addition of sodium chloride to
isotonic solution. Food and water were supplied ad libitum, and the animals were
weighed every other day after administrations of drugs.
The cytostatic agents investigated in these experiments were: Endoxan
(cyclophosphamide), mitomycin C, Nitromin (nitrogen mustard N-oxide), Thio-
TEPA (triethylene thiophosphoramide), Methotrexate (amethopterin), 5-fluoroura-
cil and Vincristine. As a control, isotonic saline solution was used.
II. Ten rats, weighing approximately 100 g., in each group were used in this
experiment. Two to three x 105 cells ofYoshida ascites sarcoma were inoculated
intracranially by the method of Lindberg and Ernster (1950). Two days after
the tumour transplantation, cytostatic agent was administered intrathecally or
intraperitoneally once only or once a day for 3 days, and the survival times ofthe
rats were observed.
RESULTS
I. (a) The results obtained in this experiment are shown in Fig. 1. The groups
which showed little difference in RISA uptake from the control group were the
following groups: Endoxan (15 mg./kg.), mitomycin C (0.03 mg./kg.), Thio-
TEPA (0-1 mg./kg.) and Methotrexate (0-15, 0-3 mg./kg.). On the contrary, the
groups: mitomycin C (0.06, 0 3 mg./kg.) and Vincristine (0.2 mg./kg.) showed
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FIG. 1.-Relative specific activities of brain to serum levels of I'3' (RISA) in rabbits killed
48 hours after intracisternal administration of Endoxan (EX), mitomycin C (MMC),
Nitromin (HN2-O), Thio-TEPA, Methotrexate (MTX), 5-Fluorouracil (5-FU), or Vincristine
(VCR).
significantly higher RISA uptake than those of the control. In the group:
Methotrexate (1 mg./kg.), there was slightly increased RISA uptake especially in
cerebrum. The animals inthe group: Nitromin (0*8 mg./kg.) diedwithin 24 hours,
and the majority in the group: 5-fluorouracil (2-5 mg./kg.), within 48 hours after
administration ofthe drug.
I. (b) The results obtained are given in Fig. 2, 3 and 4. The animals in the
groups: Endoxan (15 mg./kg.), mitomycin C (0.06 mg./kg.) and Methotrexate
(015, 0 3 mg./kg.) gained weight day by day as well as the control group and also
in the group: Thio-TEPA (0.1 mg./kg.), although there were some differences from
the controls, gained weight favourably. However, the growth of animals in the
other groups was inhibited significantly following administration of the cytostatic
agent and some ofthe animals died after marked decrease of body weight.
II. The average life span of each group is shown in Fig. 5. The survival time
of the control group was 6-1 ± 0-4 days. In the groups: Endoxan and Metho-
trexate (except the group: 5.0 mg./kg. for 3 days), the larger the quantity of the
drug administered, either intraperitoneally or intrathecally, the longer was the
life span of the animal observed. Furthermore, the life span of the group in
which the drug was administered intrathecally was remarkably longer than that
of the group in which the same quantity of the drug was administered intraperi-
toneally. As to the group in which mitomycin C was administered intrathecally,
the survival time of the group in which the quantity of the drug administered
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FiG. 2.-Changes of body weight following intrathecal administration of Endoxan (EX)
or mitomycin C (MMC) in rats.
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FIG. 3.-Changes of body weight following intrathecal administration of
Nitromin (HN2-O) or thio-TEPA in rats.
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FIG. 4.-Changes of body weight following intrathecal administration of Methotrexate (MTX),
5-fluorouracil (5-FU) or Vincristine in rats.
was more than 0-06 mg./kg. was rather shorter as compared with that ofthe group
in which the quantity ofthe drug administered was 0-03 mg./kg. for 3 days. And
in the group: mitomycin C (0.03 mg./kg. for 3 days), the life span of the intra-
thecally administered drug group was significantly longer than that of the intra-
peritoneally administered drug group.
DISCUSSION
In the chemotherapy of brain tumours, the blood-brain barrier limits the
passage of the cytostatic agent from blood to brain and by so doing, protects
normal brain tissue from the neurotoxicity of the drug (Rall, 1965). Cytostatic
agents administered intrathecally are however absorbed directly into the brain
and are liable to injure normal brain tissue. Therefore, administration by this
route must be exploited by careful selection of drugs and their doses, and as yet
little work has been done to study this.
Harbauer et al. (1965) investigated the electroencephalogram of rabbits
following the intracranial extracerebral application ofdifferent cytostatic agents-
Endoxan, Nitromin, Trenimon (trisethyleneimino-benzochinon) and tetra-
ethyleneiminobenzochinon-and suggested that only Endoxan seemed to be
suitable for local intracranial application. Extensive studies on such application
have been conducted by Heppner and his associates (Heppner etal., 1961; Heppner
and Diemath, 1963). For the first time, they tested the use of various cytostatic
agents locally on the guinea-pig brain. Then, by means of staining reactions,
spectrographical methods and radioactive tracers, they investigated the behaviour
ofcytostatic agents contained in pieces ofgelatine sponge on the brain and proved
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FIG. 5.-Effects ofintrathecal or intraperitoneal administration ofEndoxan (EX), mitomycin C
(MMC) or Methotrexate (MTX) on survival time of intracranially Yoshida sarcoma-
transplanted rats.
that Endoxan is the best agent for such application. Furthermore, this technique
has been applied, by him and his co-workers (Heppner, 1963), clinically to patients
suffering from malignant brain tumours.
In our experiments we have tried to study, by different means from those
described in the earlier reports, the selection of cytostatic agents for intrathecal
administration, and the data obtained indicate that Endoxan, Methotrexate, and
lower dose of mitomycin C may be useful for intrathecal chemotherapy of brain
tumours.
In the respect that Endoxan has little toxicity to the central nervous system
when administered intrathecally as compared with other alkylating agents, our
results are in remarkable agreement with earlier workers (Heppner, Diemath and
Jenkner, 1961; Heppner and Diemath, 1963; Harbauer et al., 1965). A possible
explanation for the results could be discussed in relation to the concept that
Endoxan is a latent alkylating agent, which is almost inactive in vitro and becomes
biologically active in vivo only upon appropriate activation (Arnold, Bourseaux
and Brock, 1958; Brock, 1963). If this conception is valid and also the activa-
tion of Endoxan takes place neither in the normal brain nor in cerebrospinal fluid,
the findings that Endoxan has little toxicity on the local normal brain tissue by
intrathecal administration could be explained. Since the demonstration by Foley
et al. (1961), the view has been widely held that Endoxan is activated primarily
by the liver and not by tumour, though at first it was believed to be activated in
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tumour cells by enzymic hydrolysis. Chirigos et al. (1962) demonstrated that En-
doxan had no effect on intracerebrally transplanted L-1210 tumour in the mouse,
either by intracerebral or by intraperitoneal administration. In this experiment,
however, intrathecal administration of Endoxan extended the survival time of
intracranially Yoshida ascites sarcoma transplanted rats. Differences of opinion
concerning the cytostatic effect of intracranial administration of Endoxan seem to
justify further examination.
There is a photometrical method of analysis of alkylating agents described by
Epstein et al. (1955) and by Friedman and Boger (1961). Recently, Morita et al.
(1965) have extended its application to analyses ofEndoxan, andtheunmetabolized
inactive form of Endoxan, which has no alkylating activity, was measured as well
as the active metabolites, which have alkylating activity. Yamada et al. (1968)
have investigated the distribution of Endoxan in cerebrospinal fluid after intra-
cisternal administration by this analytical method in dogs and demonstrated that
the concentration of the substances in alkylating state in cerebrospinal fluid
reached a considerably high level for a few hours after intracisternal administra-
tion ofEndoxan, though the concentration ratio ofactive to inactive substances of
Endoxan in cerebrospinal fluid was steadily very low. It was suggested that bio-
chemical activation of Endoxan would not take place in the cerebrospinal fluid,
but cerebrospinal fluid after intrathecal administration of Endoxan contains
considerable quantities of active substance which would chemically come to be in
alkylating state, for the concentration of Endoxan is maintained at an extremely
high level in the cerebrospinal fluid. The result of this experiment suggests that
intrathecal administration of Endoxan may be useful for the chemotherapy of
brain tumours.
Mitomycin C is a kind of antibiotic and it has been demonstrated that the
proliferation of HeLa cells which had been treated with mitomycin C at a concen-
tration of 1 pg./ml. for 1 hour was almost completely inhibited (Doi et at., 1967).
Intrathecal administration of mitomycin C (0.03 mg./kg. for 3 days) resulted in
a significantly longer extension of survival time of intracranially tumour trans-
planted rats as compared with the intraperitoneal administration of the same
quantity of the drug, but it also appeared obvious that the larger dose of mito-
mycin C by intrathecal administration was liable to cause severe brain damage
and rather to shorten the survival time of intracranial tumour-bearing rats.
These observations indicate that intrathecal administration ofmitomycin C may be
useful for chemotherapy of brain tumours, but should be tried with great caution.
Methotrexate is a kind of folic acid antagonist and should prove most effective
in tumours of the central nervous system where DNA turnover is very low as
compared to tumour (Hevesy and Ottesen, 1943). Since the demonstration of
Sansone (1954) that intrathecal administration of Methotrexate was useful for the
treatment of meningeal leukaemia, the application of the drug has been widely
used (Whiteside et al., 1958; Rieselbach et al., 1963; Hyman et al., 1965). Rubin
et al. (1966) have extended the intrathecal application of the drug to cerebrospinal
fluid perfusion for the treatment of brain tumour, and recently Norrell and Wilson
(1967) have developed a method of repetitive intrathecal administration of the
drug with the use of components of a ventriculo-atrial shunt.
Wollner et at. (1959) described local and systemic toxicity following intracister-
nal administration of Methotrexate in dogs, and Rall et al. (1962) reported that
Methotrexate was epileptogenic in unanaesthetized dogs when given intrathecally
44
495496 T. HAYAKAWA ET AL.
in concentration greater than 1 mg./ml. Rubin et al. (1966) found that 0*5-1*0
mg./ml. ofMethotrexate in cerebrospinal fluid was tolerated for cerebrospinal fluid
perfusion, and Norrell and Wilson (1967) administered Methotrexate (0.25-0.375
mg./kg.; concentration: 5 mg./ml.) through the reservoir into the cerebrospinal
fluid space clinically.
There is remarkable agreement between the earlier works and our findings,
and the available evidence indicates that Methotrexate is one ofthe most suitable
drugs for the intrathecal chemotherapy of brain tumours.
Based on the experimental findings in this series, 27 patients diagnosed as
having malignant brain tumours have been treated with intrathecal chemotherapy
in our clinic. One mg. of mitomycin C or 100 mg. of Endoxan in 20 ml. ofphysi-
ological saline solution was spread on the tumour resected area at operation, and
5 to 10 mg. of Methotrexate, twice a week was injected into the tumour resected
brain cavity through an Ommaya's reservoir (Ratcheson and Ommaya, 1968) in
the post-operative period. No serious complications followed the application of
the drug, and, though a final conclusion as to the therapeutic effects cannot yet be
drawn from the clinical data because ofthe smallnumber ofcases andthe shortness
of the follow-up period, we have a definite impression that the fate of those who
were treated with intrathecal chemotherapy in addition to surgery was somewhat
better than those who were treated only with surgery.
This study was supported in part by a grant in aid for Fundamental Scientific
Research from the Japan Welfare Ministry.
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